Highlight Therapeutics,(“Highlight”), una compañía biofarmacéutica clínica que desarrolla tratamientos antitumorales basados en RNA, y Pivotal, una CRO de implantación Europea y que ofrece se...
Pivotal announced today that it has been contracted by Checkpoint Therapeutics Inc., a New York City-based biotechnology company, to provide expert clinical research services in Europe for its upco...
Highlight Therapeutics, (“Highlight”), a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, and Pivotal, a Europe-wide full-service CRO, today announced tha...
Staidson, a biopharmaceutical company developing investigational products by targeting the complement system and Pivotal, a European-wide full-service CRO, headquartered in Madrid, have announced t...
Pivotal, a specialist CRO, has been awarded two clinical trials for a novel investigational immunotherapy drug and patient enrolment has now started. Pivotal will use its deep knowledge of Oncology...
On Tuesday, October 23rd, the European Society for Medical Oncology Congress (ESMO) ended its annual Congress in Munich with over 26,000 oncology professionals from all over the world. This congress w...